fda update tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Prescriber Insights: Navigating FDA Updates

What is less established: the very long-term (beyond five years) safety of dual GIP and GLP-1 action, and whether the bone density changes seen with significant weight loss on any medication apply to tirzepatide with the same magnitude

Stability after reconstitution is the limiting factor for multiple-dose vials

doi: 10.1111/jam.14490 138 GrayK

Rapid weight loss using full meal replacement in combination with medical supervision is safe and healthy

Our mission centers on delivering accessible, affordable, and top-notch healthcare solutions to individuals and communities spanning multiple states

The dosing schedules for the Wegovy pill and injection are different